Compare Charles River Laboratories Intl. Inc (CRL) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs PubMatic Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $287.32 (market cap $13.46B), while PubMatic Inc trades at $17.4 (market cap $804.41M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 16.7× PubMatic Inc's market cap. Which is the better fit depends on your goals.
| CRL | PUBM | |
|---|---|---|
Market Cap | $13.46B | $804.41M |
Sector | Health | Technology |
52-Week High | $282.00 | $17.78 |
52-Week Low | $145.57 | $6.28 |
Enterprise Value | $16.30B | $707.54M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
PubMatic trades at $17.39, down 2.08% today, with a bullish technical outlook from moving averages but overbought RSI signals. Revenue reached $282.93M in 2025, though net income was negative. Recent Q2 2026 earnings beat expectations with 10.5% revenue growth, and the company appointed a new Chief Revenue Officer to drive AI-advertising growth.
The stock offers upside to the $20.83 consensus price target, supported by analyst buy ratings and operational cash flow strength. Risks include persistent unprofitability, high P/E ratio, and CFO transition. Positive sentiment from recent earnings beats and strategic hires suggests potential for recovery if margin improvements continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
